Smith R - Search Results

1

Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.

de Jonge MJ, Punt CJ, Sparreboom A, Planting AS, Peters ME, van De Schraaf J, Jackman A, Smith R, de Mulder PH, Verweij J. de Jonge MJ, et al. Among authors: smith r. J Clin Oncol. 2002 Apr 1;20(7):1923-31. doi: 10.1200/JCO.2002.07.057. J Clin Oncol. 2002. PMID: 11919253 Clinical Trial.

2

Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.

de Jonge MJ, Glimelius B, Verweij J, Van Groeningen C, Bonneterre J, de Vries EG, Culine S, Young J, Smith R, Droz J. de Jonge MJ, et al. Among authors: smith r. Anticancer Drugs. 2002 Jul;13(6):645-53. doi: 10.1097/00001813-200207000-00012. Anticancer Drugs. 2002. PMID: 12172511 Clinical Trial.

3

A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.

Plummer R, Rees C, Hughes A, Beale P, Highley M, Trigo J, Gokul S, Judson I, Calvert H, Jackman A, Mitchell F, Smith R, Douglass E. Plummer R, et al. Among authors: smith r. Clin Cancer Res. 2003 Apr;9(4):1313-22. Clin Cancer Res. 2003. PMID: 12684399 Clinical Trial.

4

Phase I study of an oral formulation of ZD9331 administered daily for 28 days.

Sawyer MB, Ratain MJ, Bertucci D, Smith RP, Schilsky RL, Vogelzang NJ, Shulman K, Douglass EC, Fleming GF. Sawyer MB, et al. J Clin Oncol. 2003 May 1;21(9):1859-65. doi: 10.1200/JCO.2003.01.148. J Clin Oncol. 2003. PMID: 12721264 Clinical Trial.

5

Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.

Rees C, Beale P, Trigo JM, Mitchell F, Jackman A, Smith R, Douglass E, Judson I. Rees C, et al. Among authors: smith r. Clin Cancer Res. 2003 Jun;9(6):2049-55. Clin Cancer Res. 2003. PMID: 12796367 Clinical Trial.

6

Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.

Miller VA, Johnson DH, Krug LM, Pizzo B, Tyson L, Perez W, Krozely P, Sandler A, Carbone D, Heelan RT, Kris MG, Smith R, Ochs J. Miller VA, et al. Among authors: smith r. J Clin Oncol. 2003 Jun 1;21(11):2094-100. doi: 10.1200/JCO.2003.12.008. J Clin Oncol. 2003. PMID: 12775734 Clinical Trial.

7

Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.

Zhang L, Li S, Zhang Y, Zhan J, Zou BY, Smith R, Martin PD, Jiang Y, Liao H, Guan Z. Zhang L, et al. Among authors: smith r. Clin Ther. 2011 Mar;33(3):315-27. doi: 10.1016/j.clinthera.2011.04.005. Clin Ther. 2011. PMID: 21600385 Clinical Trial.

8

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.

Fury MG, Solit DB, Su YB, Rosen N, Sirotnak FM, Smith RP, Azzoli CG, Gomez JE, Miller VA, Kris MG, Pizzo BA, Henry R, Pfister DG, Rizvi NA. Fury MG, et al. Among authors: smith rp. Cancer Chemother Pharmacol. 2007 Mar;59(4):467-75. doi: 10.1007/s00280-006-0286-6. Epub 2006 Aug 1. Cancer Chemother Pharmacol. 2007. PMID: 16896930 Clinical Trial.

9

Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.

Michael M, Gibbs P, Smith R, Godwood A, Oliver S, Tebbutt N. Michael M, et al. Among authors: smith r. Invest New Drugs. 2009 Jun;27(3):253-61. doi: 10.1007/s10637-008-9182-8. Epub 2008 Nov 11. Invest New Drugs. 2009. PMID: 19002384 Clinical Trial.

10

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE 2nd, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, Lyons P, Tourt-Uhlig S, Bigner DD, Friedman HS, Rich JN. Reardon DA, et al. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):860-8. doi: 10.1158/1078-0432.CCR-05-2215. Clin Cancer Res. 2006. PMID: 16467100 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24,035 results

Search Page